Natera (NTRA): A 13.6% Revenue Beat - And That Is The Base Rate

Natera, Inc. (NTRA) Q2 2026 — Q2 revenue $752.8M, +37.7% YoY, vs a $662.6M consensus - a 13.6% beat. GAAP EPS $(0.47) vs a $(0.51) bar. Gross margin 64.5%; operating margin -10.1% vs -20.2%. FY26 revenue guidance RAISED $100M at the midpoint to $2.85B-$2.91B. AMC print, so the $265.38 close is PRE-print; the stock traded near $308 after hours, about +16.3%. Natera posted an excellent quarter and we still rate it SELL - those are two different questions. The fact nobody put on screen: Natera has beaten the revenue consensus by DOUBLE DIGITS for eight straight quarters, median 13.3%, so tonight's 13.6% beat WAS the average - and the stock rose 16% on it. Full arithmetic below. THE CALL: SELL (4/5, AN EXCEPTIONAL BUSINESS AT A PRICE THAT NEEDS A DECADE OF PERFECTION) — base-case value ~$132.0 vs ~$308.0 today. KEY METRICS: - CALL: SELL 4/5, base case fair value ~$132 vs a ~$308 after-hours print (-57%) and the $265.38 close (-50%). Bull $192, base $132, bear $61 - even our BULL case is 38% below tonight's price. Street: 27 analysts, 24 Buy / 3 Hold / 0 Sell, consensus Buy, $274.45 avg target (median $275, low $220, high $330) - already 11% BELOW the after-hours price. We are far more CAUTIOUS and DIFFER on the word. - THE PRINT: revenue $752,750K vs $546,600K (+37.7%) vs a $662.6M consensus = a 13.6% beat. Gross profit $485.2M, GM 64.5% vs 63.4%. R&D $228.1M (+55.8%); SG&A $327.2M (+5.4%); amortisation $5.7M. Loss from operations $(75.8)M vs $(110.4)M, -10.1% vs -20.2%. Net loss $(67.0)M = $(0.47)/sh vs $(0.74); bar $(0.51). WASO 143.3M. H1 revenue $1,449.4M, H1 net loss $(152.1)M. - THE BEAT IS THE BASE RATE: eight straight double-digit revenue beats (+21.7%, +9.3%, +12.5%, +14.8%, +15.3%, +10.2%, +12.9%, +13.6%), median 13.3%. Cause: revenue is booked on an ESTIMATE of insurer collections and trued up later - a $52.3M change in estimate this quarter vs $61.0M in Q1 2026 and $45.3M in Q2 2025. Ex-true-up revenue $700.5M vs $501.3M = +39.7%, FASTER than the headline. The beat is real, not an artifact. - THE CUT BAR (3 checks): (1) H1 revenue $1,449.4M vs an implied H2 of $1,430.6M at the $2,880M FY midpoint - H2 is $18.8M SMALLER than H1. (2) That implied H2 is +13.8% YoY after +38.2% in H1. (3) The midpoint rose exactly $100M while Q2 alone beat by $90.1M. FY26 guide: revenue $2.85-2.91B, GM 64-66%, SG&A $1.125-1.225B, R&D $800-900M, cash flow positive. - THE LOSS IS A CHOICE: gross profit +$138.6M YoY; R&D took $81.6M (59% of it, +55.8%, now 30.3% of revenue vs 26.8%); SG&A took $16.7M (+5.4% on 37.7% growth - SG&A fell from 56.8% to 43.5% of revenue, 13 points of leverage); amortisation $5.7M; leaving $34.6M = exactly the improvement in operating loss. Flat R&D = a $5.8M operating PROFIT instead of a $75.8M loss. - VOLUMES + RISK: tests processed 1,043,900 (+22.4%); reported 985,500 (+21.2%); oncology 296,700 (+57.2%); clinical MRD units +34,000 sequentially, a record. Revenue per test $763.82 vs $672.40. Signatera CDx FDA-approved in MIBC (IMvigor011); Prospera MolDx expansion effective Aug 30 2026. Guardant Health holds a $292.5M jury verdict vs Natera, unaccrued in $836.0M of total liabilities. - CASH + VALUATION: cash $1,091.5M less $80.3M credit and $120.5M contingent consideration = ~$891M net cash; cash rose only $3.6M in the quarter. FY2025 operating cash flow $215.3M against $354.4M of SBC - charge the stock and 2025 owner cash was NEGATIVE $139M. AR $296.5M to $422.0M, DSO ~41 to ~51 days. At ~$308, EV $43,342M = 15.0x FY26 revenue and 23.2x gross profit. Owner-earnings DCF (SBC charged in full, WACC 9.0%) = $19,855M = ~$132/share. What to watch: UP: R&D flat for two consecutive quarters, or a GAAP operating profit before 2028. BEAR: a Medicare rate cut on Signatera or Prospera, a true-up that reverses, or DSO past 60 days. Next read: Q3 2026, early November. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.